SCHEMBL669576

SCHEMBL669576

CCOC(=O)c1cc(Br)ccc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 4/20 0.50
MAPT P10636 3/20 0.50
GABRA1 P14867 1/20 0.50
GABRB1 P18505 1/20 0.50
GABRA3 P34903 1/20 0.50
GABRB2 P47870 1/20 0.50
GFER P55789 1/20 0.50
HSD17B10 Q99714 1/20 0.50
STAT3 P40763 1/20 0.50
KDM4E B2RXH2 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
HSD17B2 P37059 1/20 0.49
TSHR P16473 1/20 0.49
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4601189 0.87 PTGDR2 (0.51) ALDH1A1SMN1; SMN2LMNAMAPTGABRA1
SCHEMBL3084121 0.85 CYP3A4 (0.50) ALDH1A1CYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL2096332 0.85 LMNA (0.57) ALDH1A1SMN1; SMN2LMNAMAPTHSD17B2
SCHEMBL20855885 0.84 ALDH1A1 (0.51) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL8176195 0.84 ALDH1A1 (0.46) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL28151088 0.83 ALDH1A1 (0.48) ALDH1A1CYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL30361998 0.83 ALDH1A1 (0.59) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL392403 0.83 ALDH1A1 (0.59) ALDH1A1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL234030 0.83 TSHR (0.60) ALDH1A1SMN1; SMN2LMNAMAPTGABRA1
SCHEMBL2091159 0.82 HSD17B2 (0.67) ALDH1A1CYP1A2SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9849109-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2017-12-26 US disclosed
EP-2606031-B1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
EP-2822931-B1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2 INC (US) 2017-05-03 EP disclosed
EP-2822931-B1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2 INC (US) 2017-05-03 EP disclosed
US-9505728-B2 Triazolone compounds and uses thereof INCEPTION 2, INC. (US) 2016-11-29 US disclosed
US-9505728-B2 Triazolone compounds and uses thereof INCEPTION 2, INC. (US) 2016-11-29 US disclosed
US-9505728-B2 Triazolone compounds and uses thereof INCEPTION 2, INC. (US) 2016-11-29 US disclosed
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2015-06-18 US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 US disclosed
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2015-03-19 US disclosed
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2015-03-19 US disclosed
EP-2822931-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF Inception 2, Inc. (US) 2015-01-14 EP disclosed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO disclosed
WO-2013134562-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2, INC. (US) 2013-09-12 WO disclosed
EP-2606031-A2 AUTOTAXIN INHIBITORS AND USES THEREOF Amira Pharmaceuticals, Inc. (US) 2013-06-26 EP disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 US disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 WO disclosed
US-7265245-B2 Compounds useful for the treatment of diseases associated with the formation of amyloid fibrils INNOVAPROTEAN, S.L (ES) 2007-09-04 US disclosed
US-20070167378-A1 COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS INNOVAPROTEAN, S.L. (ES) 2007-07-19 US disclosed
EP-1679299-A1 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS Innovaprotean, S.L. (ES) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 ALDH1A1 4786/4885CYP1A2 4759/4885CYP2C9 4839/4885
US-20150080412-A1 TRIAZOLONE COMPOUNDS AND USES THEREOF PPARA, PPARG, PPARD ALDH1A1 673/4885CYP1A2 706/4885CYP2C9 1476/4885
US-20150164861-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 ALDH1A1 4786/4885CYP1A2 4759/4885CYP2C9 4839/4885
US-20070167378-A1 COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE FORMATION OF AMYLOID FIBRILS APP, C1R, RTN3 ALDH1A1 1030/4885CYP1A2 1470/4885CYP2C9 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.